SEC Form 4 · accession 0001209191-16-129046
ImmunoCellular Therapeutics, Ltd. · IMUC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John S Yu
Director
Period of report
Jun 17, 2016
Accepted (ET)
Jun 21, 2016 · 4:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822411
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.24 | Jun 17, 2016 | A | 156,750 | A | — | Jun 16, 2026 | Common Stock | 156,750 | 156,750 | D |
Explanation of responses
- F1The option vests in equal quarterly installments for one year following June 17, 2016.